Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG (Nasdaq: CRSP) files detailed reports with the U.S. Securities and Exchange Commission that document its financial condition, clinical pipeline progress, collaborations, and capital markets activity. On this SEC filings page, Stock Titan aggregates CRSP’s regulatory documents and pairs them with AI-powered summaries to help readers interpret the implications of each filing.
For a gene editing biopharmaceutical company like CRISPR Therapeutics, annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe the status of programs such as CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, in vivo liver editing candidates like CTX310 and CTX320, SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, zugo-cel in autoimmune and oncology indications, and siRNA collaborations such as SRSD107/CTX611 with Sirius Therapeutics. These reports also outline risk factors, research and development priorities, and collaboration structures with partners including Vertex Pharmaceuticals.
Current reports on Form 8-K provide more focused updates on material events, such as quarterly financial results, business updates, and capital-raising actions. For example, recent 8-K filings describe the announcement of quarterly results and the use of an at-the-market equity program under an Open Market Sale Agreement with Jefferies to offer additional common shares under a shelf registration statement.
Investors can also use this page to monitor registration statements, prospectus supplements, and other offering-related filings that detail how CRISPR Therapeutics issues new equity, as well as any proxy materials that address governance and shareholder matters. Stock Titan’s tools surface new CRSP filings in near real time from EDGAR and apply AI-generated highlights so readers can quickly locate key disclosures on clinical data, collaboration terms, cash runway, and share issuance without reading every page.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported an RSU vesting and related share sale. On
On
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On
On
CRISPR Therapeutics AG is raising capital through a private offering of $550 million aggregate principal amount of convertible senior notes due 2031, sold to qualified institutional buyers. The offering was upsized from a previously proposed $350 million.
The notes carry an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax, and mature on March 1, 2031 unless earlier converted, redeemed or repurchased. They are initially convertible at 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a roughly 45% premium to the $52.80 share price on March 10, 2026. CRISPR Therapeutics estimates net proceeds of approximately $536.3 million, or $585.2 million if the purchasers’ option is fully exercised, and plans to use the funds for general corporate purposes.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related share sale. On February 18, 2026, he acquired 13,250 Common Shares at $0.00 per share through the exercise/settlement of restricted stock units.
On February 19, 2026, he sold 6,967 Common Shares at an average price of $52.58 per share. A footnote explains that this sale was required to cover tax withholding obligations under the company’s RSU Settlement Policy and was not a discretionary trade. After these transactions, he directly held 226,106 Common Shares.
The restricted stock units were originally granted on February 18, 2022 for 53,000 Common Shares, vesting in four equal annual installments through February 18, 2026.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity transactions involving company stock. On February 18, 2026, he acquired 3,825 Common Shares through the exercise and settlement of restricted stock units at a price of $0.00 per share, increasing his direct holdings to 87,227 Common Shares. On February 19, 2026, 2,112 Common Shares were sold at an average price of $52.58 per share to cover tax withholding obligations related to the RSU vesting, as required by the company’s RSU Settlement Policy and not as a discretionary trade. After these transactions, he directly owned 85,115 Common Shares.
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report beneficial ownership of 5,950,145 shares of CRISPR Therapeutics common stock, representing 6.2% of the class as of 12/31/2025. Orbis holds 5,934,328 shares and Allan Gray holds 15,817 shares, each with sole voting and dispositive power over its respective holdings.
Both firms are non-U.S. institutions equivalent to investment advisers and state that the securities are held in the ordinary course of business, not to change or influence control of CRISPR Therapeutics. Other persons have rights to receive dividends or sale proceeds on the shares each firm beneficially owns.
CRISPR Therapeutics describes its business as a leader in CRISPR/Cas9 gene-editing medicines, highlighted by CASGEVY, the first approved CRISPR-based therapy for severe sickle cell disease and transfusion‑dependent beta thalassemia in patients 12 and older across multiple regions.
The company outlines four core franchises: hemoglobinopathies, in vivo liver gene editing, allogeneic CAR T cell therapies for autoimmune diseases and oncology, and regenerative medicine for Type 1 diabetes. It estimates about 60,000 eligible SCD and TDT patients in key Western and Middle Eastern markets.
Pipeline updates include CTX310 in Phase 1b for cardiovascular disease, where a single-course treatment cut ANGPTL3 by up to 89%, triglycerides by up to 84%, and LDL by up to 87% in early data, and CTX611, a long‑acting siRNA Factor XI inhibitor now in Phase 2. Zugo‑cel, its next‑generation allogeneic CD19 CAR T, shows high response rates in relapsed or refractory large B‑cell lymphoma and early remission signals in systemic lupus erythematosus.
CRISPR Therapeutics reported fourth quarter and full-year 2025 results, showing early CASGEVY commercialization alongside higher losses as it invests in its pipeline. CASGEVY generated $54 million in Q4 2025 revenue and $116 million for the full year, with 64 patients infused in 2025 and 147 initiating treatment.
Cash, cash equivalents and marketable securities were $1,975.8 million as of December 31, 2025, slightly above $1,903.8 million a year earlier. Q4 2025 R&D expense rose to $83.5 million from $71.7 million, and collaboration expense jumped to $53.7 million from $10.4 million due to the absence of a prior-year cost deferral.
Net loss widened to $130.6 million for Q4 2025 versus $37.3 million a year ago, and to $581.6 million for 2025 versus $366.3 million in 2024. The company highlighted progress across in vivo liver editing, its siRNA collaboration, autoimmune and oncology CAR-T programs, and regenerative medicine, with multiple clinical and data updates expected in 2026.
Capital International Investors filed an amended Schedule 13G reporting its beneficial ownership of common stock of CRISPR Therapeutics AG. The firm is deemed to beneficially own 1,186,794 shares, representing 1.2% of the issuer’s 95,300,233 shares believed to be outstanding.
Capital International Investors reports sole voting and sole dispositive power over all reported shares and no shared power. The filer also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of CRISPR Therapeutics AG.
CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025. This direct ownership transaction brought his total reported holdings to 1,508 shares.
The filing notes this purchase was matchable under Section 16(b) with a later sale of 1,508 shares at $35.94 per share on May 29, 2025 under a mandatory “sell to cover” for a vested restricted stock unit. Patel agreed to pay CRISPR Therapeutics $4,493.84, equal to the full short-swing profit.